Zepbound

Zepbound patients lose 20–26% body weight at 72 weeks in clinical trials. Here’s the timeline, plateau patterns, and what happens after stopping treatment.

Zepbound 2-year results show sustained weight loss averaging 18-21% from baseline in clinical trials with durable metabolic improvements across completion

Zepbound 5 year results show sustained weight loss in 62% of patients who maintain treatment, but data comes from extension studies, not full five-year

Zepbound (tirzepatide) reduces appetite and muscle recovery time — understand the trade-offs before using GLP-1s in athletic contexts.

Zepbound affects CrossFit performance through muscle preservation, recovery timing, and energy availability — here’s what athletes need to know before

Zepbound powerlifting use involves risks: muscle loss, decreased strength output, and compromised recovery. Learn how GLP-1 impacts performance.

Zepbound affects endurance, recovery, and race-day energy in marathon runners. Learn safe dosing timelines, GI management strategies, and when to pause

Zepbound cyclists face unique challenges balancing GLP-1 therapy with endurance demands. We break down nutrition timing, glycogen management, and training

Zepbound triathletes face unique challenges: GLP-1 medications affect endurance capacity, recovery timing, and metabolic adaptation during